Company / EPS (Diluted)
iBio, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$6.50
FY2025
5-year range
-$106.19 / -$0.61
FY2021-FY2025
Trend
+93.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2025 after 3 years of decline, reaching $-6.50.
Based on SEC 10-K filings.
-6.50 in FY2025.
Declined from $-5.78 to $-6.50 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 93.9% year-over-year.
- Peak eps (diluted) was recorded in FY2016.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.36 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$6.50 | +93.9% |
| FY2024 | -$106.19 | -1737.2% |
| FY2023 | -$5.78 | -92.7% |
| FY2022 | -$3.00 | -391.8% |
| FY2021 | -$0.61 | +35.1% |
| FY2020 | -$0.94 | +39.0% |
| FY2019 | -$1.54 | +6.1% |
| FY2018 | -$1.64 | -1266.7% |
| FY2017 | -$0.12 | -33.3% |
| FY2016 | -$0.09 | -50.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026